VolitionRX (NYSEAMERICAN:VNRX) Announces Quarterly Earnings Results

VolitionRX (NYSEAMERICAN:VNRX) issued its earnings results on Thursday. The medical research company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.15), FiscalAI reports. The business had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.41 million.

VolitionRX Price Performance

Shares of VNRX stock traded down $0.04 during trading on Thursday, reaching $0.63. The company had a trading volume of 825,091 shares, compared to its average volume of 471,390. The firm’s 50 day simple moving average is $1.19 and its two-hundred day simple moving average is $2.79. VolitionRX has a one year low of $0.60 and a one year high of $15.10. The company has a market capitalization of $5.44 million, a PE ratio of -0.15 and a beta of 1.16.

Hedge Funds Weigh In On VolitionRX

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new stake in shares of VolitionRX in the fourth quarter worth $28,000. Virtu Financial LLC grew its stake in VolitionRX by 166.6% in the 4th quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock valued at $28,000 after buying an additional 67,848 shares during the last quarter. Squarepoint Ops LLC acquired a new position in VolitionRX in the 4th quarter valued at $34,000. Northwestern Mutual Wealth Management Co. bought a new position in VolitionRX in the 2nd quarter worth $52,000. Finally, Citadel Advisors LLC raised its holdings in VolitionRX by 70.1% in the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after acquiring an additional 135,775 shares during the period. Institutional investors and hedge funds own 8.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on VNRX shares. Citigroup downgraded VolitionRX to a “hold” rating in a report on Monday, April 20th. D. Boral Capital reiterated a “hold” rating on shares of VolitionRX in a research note on Monday, April 20th. Benchmark reissued a “hold” rating on shares of VolitionRX in a research report on Tuesday, June 2nd. Finally, Maxim Group restated a “buy” rating and set a $4.00 price target on shares of VolitionRX in a research note on Thursday, June 18th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $28.00.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.